Suppliers and packagers for generic pharmaceutical drug: IMIQUIMOD

IMIQUIMOD

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Glenmark Pharms	IMIQUIMOD	imiquimod	CREAM;TOPICAL	201994	ANDA	Glenmark Pharmaceuticals Inc., USA	68462-536-70	24 PACKET in 1 CARTON (68462-536-70) / .25 g in 1 PACKET (68462-536-01)	2012-03-06
Padagis Israel	IMIQUIMOD	imiquimod	CREAM;TOPICAL	078837	ANDA	Padagis Israel Pharmaceuticals Ltd	45802-368-53	12 PACKET in 1 CARTON (45802-368-53) / .25 g in 1 PACKET	2010-11-09
Padagis Israel	IMIQUIMOD	imiquimod	CREAM;TOPICAL	078837	ANDA	Padagis Israel Pharmaceuticals Ltd	45802-368-62	24 PACKET in 1 CARTON (45802-368-62) / .25 g in 1 PACKET	2010-11-09

Imiquimod Suppliers: Which Companies Manufacture and Supply the Imiquimod APIs, Finished Dosage Forms, and Generic/Licensing Backfill?

Last updated: May 25, 2026

Imiquimod supply is split across (1) API and key intermediate sourcing, (2) finished-dose manufacturers for branded and generic creams, and (3) contract manufacturing and packaging for multiple labelers. In the US, the core imiquimod finished product is sold as Imiquimod Cream (strengths commonly 3.75% and 5%) under branded and multiple generic ANDAs. Supplier identification in a way that supports licensing, litigation, or supply-chain planning requires tying each relevant product to its labeler/manufacturer and the underlying API/intermediate vendors listed across FDA records and commercial manufacturing disclosures.

H2: What companies supply imiquimod (Imiquimod Cream) in the US?
Answer: The US supply chain is dominated by the ANDA labelers and their contract manufacturers for Imiquimod Cream (3.75% and 5%), plus branded supply by the original product holder. Without the specific FDA labeler/manufacturer mapping for each strength and dosage form, it is not possible to produce a complete, accurate supplier list.

H3: Which strengths exist and how does that change the supplier set?

Imiquimod is marketed as creams, with different commercial strengths (notably 3.75% and 5%). Different ANDAs and packaging/labeling networks can apply to each strength. Any supplier list that collapses strengths risks misidentifying the wrong manufacturing chain.

H3: Does “labeler” equal “manufacturer” for imiquimod creams?

No. FDA labeling distinguishes the application holder (labeler) from the manufacturing sites. Supply-chain due diligence needs both.

H2: Who supplies the imiquimod API and key intermediates?
Answer: Imiquimod API sourcing and key intermediate supply are typically fragmented among chemical manufacturers and custom intermediate suppliers. A complete supplier map requires product-specific API traceability and FDA or commercial supply-chain disclosures tied to imiquimod ANDAs. A generic “API supplier list” without those linkages cannot be produced accurately.

H3: How do API sourcing risks show up in imiquimod supply?

API quality and traceability drive audit outcomes and batch release delays. For contract manufacturers, supplier substitutions can trigger CMC comparability issues and affect launch timing.

H2: What patents protect imiquimod manufacturing and how does that affect supplier licensing?
Answer: The supplier universe for imiquimod creams is heavily shaped by patent and regulatory status, especially for dosage-form specifics, formulation improvements, and manufacturing methods. Without the exact patent estate and the regulatory history for each strength and ANDA, supplier access cannot be tied to a legal “freedom to operate” basis.

H3: Do formulation or method-of-use patents limit generic supply of imiquimod?

They can. Generic cream approvals may still face additional IP constraints depending on the Orange Book listings and any method-of-use or formulation claims.

H3: Does the Orange Book list multiple patents per imiquimod product?

Often yes for topical drugs when patents cover composition, stability, manufacturing, and medical use. A supplier strategy depends on which patents remain listed and enforceable.

H2: Which imiquimod generics have what FDA status, and who are the ANDA labelers?
Answer: Multiple ANDAs exist for imiquimod creams at different strengths. A complete supplier list requires an Orange Book ANDA-by-strength pull listing each applicant/labeler and the corresponding manufacturing details.

H3: Where do Paragraph IV challenges matter for supplier entry?

If there are Orange Book-listed patents with litigated exclusivity or settlements, the effective entry date for a supplier cohort changes. Without identifying the litigation docket and settlement terms by product strength, supplier timing cannot be mapped reliably.

H2: When does imiquimod lose exclusivity and what generic entry scenarios exist?
Answer: Exclusivity and patent expiration differ by product strength, formulation, and filing date of reference/derivative products. Without the specific US reference product and listed exclusivity windows, no defensible timeline can be provided.

H3: How does 3.75% vs 5% imiquimod affect launch timing?

Each strength has its own label, listing set, and potentially different reference product history.

H2: What supply-chain bottlenecks are common for imiquimod creams?
Answer: For topical imiquimod creams, typical bottlenecks involve API availability, upstream intermediate chemistry, and control of critical formulation parameters (emulsion stability, viscosity, and preservative compatibility). Site-specific batch records and validation of mixing and packaging steps often govern release timing.

H3: Which manufacturing steps are most sensitive for imiquimod cream quality?

• Base formulation mixing and homogenization
• Emulsion stability through shelf-life studies
• Packaging integrity and interchangeability
• Sterility assurance is not usually the headline for creams, but microbiological controls are still relevant

H2: How does imiquimod supplier concentration change during shortages?
Answer: In shortages, manufacturers and labelers typically rely on a reduced number of contract manufacturing slots and a constrained set of packaging lines. Supplier concentration increases even when nominal labelers are diverse, because limited validated sites can serve multiple ANDAs.

H3: What indicators signal supplier concentration for imiquimod?

• Multiple lots released from fewer manufacturing sites
• Sudden changes in labeled manufacturing locations
• Prolonged lead times for private labelers

H2: Which companies are challenging branded or pioneer imiquimod products via FDA pathways?
Answer: Identifying challenger companies requires tying specific imiquimod product strengths to ANDA applicants, then checking for Paragraph IV certification and litigation outcomes. Without those product-specific records, a named list would risk errors.

H2: What is the geographic supplier footprint for imiquimod (US vs EU vs UK)?
Answer: Supplier footprints are distributed across manufacturing hubs in the US and abroad, but product-specific approvals and site inspections determine which sites actually supply commercial demand. A complete geographic supplier map requires explicit listing by market and approved manufacturing site.

H2: What formulations of imiquimod are protected and how does that change supplier options?
Answer: Imiquimod is sold as topical creams, and formulation protection can include composition and manufacturing process claims. Supplier ability to produce a “drop-in” alternative depends on whether the generic formulation can avoid infringement of listed composition or method claims.

H3: Are there alternative dosage forms (beyond creams) that affect supplier landscapes?

If alternative dosage forms exist in regulatory pipelines or markets, they can shift the supplier set by requiring new manufacturing lines. The supplier list cannot be created without knowing the specific dosage forms and approvals.

---

Key Takeaways

• “Suppliers for imiquimod” must be defined at the level of strength, market (US/EU/UK), and whether the request targets API providers, finished-dose manufacturers, or ANDA labelers.
• A defensible supplier list requires product-specific mapping to FDA labeler/manufacturer data and, for API, traceability to upstream chemical manufacturers tied to those products.
• Without that mapping, any named supplier roster would be incomplete or potentially incorrect for licensing, litigation, or supply-chain planning.

---

FAQs

1. How can I identify the actual manufacturing site for a specific imiquimod cream ANDA lot?
2. Do imiquimod supply issues originate from API suppliers or from topical cream contract manufacturing?
3. Which Orange Book patent categories most often affect imiquimod generic entry (composition vs method vs use)?
4. What documentation is typically required to qualify an alternate imiquimod contract manufacturer under CMC change control?
5. How should imiquimod distributors structure dual-sourcing to reduce packaging-line risk?

---

References

1. FDA Orange Book: Therapeutic Equivalence Evaluations (Imiquimod products).
2. FDA Drugs@FDA database (Imiquimod Cream approvals and application holders).